Corvus Pharmaceuticals (CRVS) Change in Receivables (2021 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Change in Receivables of $6000.0 in Q1 2026, up 20.0% quarter-over-quarter from $5000.0 in Q4 2025, and up 50.0% on a YoY basis from $4000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Change in Receivables (2021 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Change in Receivables history runs 6 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 50.0% year-over-year to $6000.0; the TTM figure through Mar 2026 stood at -$36000.0 (down 161.02% YoY), while the FY2025 annual figure was -$38000.0, down 177.55% from the prior year.
- Change in Receivables was $6000.0 for Q1 2026 at Corvus Pharmaceuticals, up from $5000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $130000.0 in Q3 2022 to a low of -$429000.0 in Q2 2023.
- Historically, Change in Receivables has averaged -$33785.7 across 5 years, with a median of $5500.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables soared 218.18% in 2024, then tumbled 254.29% in 2025.
- A 5-year view of Change in Receivables shows it stood at $85000.0 in 2022, then slumped by 82.35% to $15000.0 in 2023, then tumbled by 66.67% to $5000.0 in 2024, then changed by 0.0% to $5000.0 in 2025, then gained by 20.0% to $6000.0 in 2026.
- The last three Change in Receivables figures came in at $6000.0 (Q1 2026), $5000.0 (Q4 2025), and -$54000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | -54,000.00 |
| Sep 30, 2025 | -54,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Sep 30, 2023 | 11,000.00 |
| Jun 30, 2023 | -429,000.00 |
| Jun 30, 2023 | -429,000.00 |